Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
intravenous immunoglobulin |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
1986 |
| gptkbp:ATCCode |
gptkb:J06BA02
|
| gptkbp:contains |
gptkb:immunoglobulin_G
|
| gptkbp:contraindication |
IgA deficiency with antibodies against IgA
|
| gptkbp:form |
solution for infusion
|
| gptkbp:halfLife |
23-25 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gammagard
|
| gptkbp:indication |
autoimmune diseases
immunodeficiency disorders |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:mechanismOfAction |
provides passive immunity by supplying antibodies
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea fatigue headache chills |
| gptkbp:storage |
2-8°C
|
| gptkbp:usedFor |
gptkb:chronic_inflammatory_demyelinating_polyneuropathy
immunodeficiency |
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|